Caris Life Sciences, Inc.

Listed Company

CAICIK 0002019410NasdaqNon-AcceleratedEmerging GrowthServices-Medical LaboratoriesTexasFY ends Dec 31

Period

FY 2025

Revenue

$812.03M

Net Income

$-68.09M

Total Assets

$1.13B

Equity

$577.31M

Shares Out

282.58M

Op. Cash Flow

$83.16M

Business

Caris Life Sciences, Inc. is a publicly listed company in Medical Laboratories, incorporated in Texas. Common stock trades on Nasdaq under the ticker CAI.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Total revenue	812	412	306
Selling and marketing expense	168	153	143
General and administrative expense (see note 11)	225	169	149
Research and development expense	102	114	117
Total costs and operating expenses	767	669	626
Income (Loss) from operations	45	−257	−320
Interest income	16	7	11
Interest expense	−57	−50	−32
Changes in fair value of financial instruments	−52	18	11
Other expense, net	−21	−349,000	−13
Total other expense, net	−113	−25	−22
Loss before income taxes and provision for income taxes	−68	−282	−341
Provision for income taxes	0	0	0
Net loss	−68	−282	−341
Unrealized gain on available-for-sale securities	0	7,000	−2
Foreign currency translation adjustments	726,000	−15,000	180,000
Comprehensive loss	−67	−282	−343
Deemed dividend from Series D redeemable convertible preferred stock (see note 6)	−384	0	0
Adjustments of redeemable convertible preferred stock to redemption value	−85	−96	−121
Net loss attributable to common shareholders basic	−538	−378	−463
Net loss attributable to common shareholders diluted	−538	−378	−463
Net loss per share attributable to common shareholders, basic (in dollars per share)	−3.22	−10.66	−13.24
Net loss per share attributable to common shareholders, diluted (in dollars per share)	−3.22	−10.66	−13.24
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic (in shares)	167	35	35
Weighted-average shares used in computing net loss per share attributable to common shareholders, diluted (in shares)	167	35	35

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-06-30	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash, cash equivalents, and restricted cash	798	—	65	—	—
Short-term marketable securities	2	—	2	—	—
Accounts receivable	112	—	88	—	—
Supplies	64	—	40	—	—
Prepaid expenses and other current assets	22	—	20	—	—
Total current assets	998	—	216	—	—
Property and equipment, net	63	—	68	—	—
Goodwill	19	—	19	—	—
Other assets	45	—	41	—	—
Total assets	1,126	—	344	—	—
Accounts payable	39	—	28	—	—
Accrued expenses and other current liabilities	88	—	78	—	—
Current portion of indebtedness	169,000	—	60	—	—
Total current liabilities	127	—	165	—	—
Long-term indebtedness, net of debt discounts	379	—	319	—	—
Warrant liabilities	0	—	92	—	—
Other long-term liabilities	42	—	44	—	—
Total liabilities	548	—	621	—	—
Commitments and contingencies (see note 10)	—	—	—	—	—
Redeemable convertible preferred stock	0	2,446	2,222	2,125	1,954
Preferred stock	0	—	0	—	—
Common stock	283,000	—	38,000	—	—
Treasury stock	−17	—	−330,000	—	—
Additional paid-in capital	3,142	—	0	—	—
Related party promissory note receivable (see note 7)	0	—	−27	—	—
Accumulated deficit	−2,549	—	−2,472	—	—
Accumulated other comprehensive income	936,000	—	210,000	—	—
Total shareholders' equity (deficit)	577	—	−2,499	−2,145	−1,702
Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit)	1,126	—	344	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Depreciation and amortization	23	49	49
Stock-based compensation expense	70	19	15
Non-cash operating lease expense	6	6	4
Amortization of debt discounts	13	7	5
Changes in fair value of financial instruments	52	−18	−11
Loss on debt extinguishment	20	0	11
Other	1	4	−1
Accounts receivable	−30	−34	−15
Supplies	−21	5	−4
Prepaid expenses and other current assets	−5	−1	5
Other assets	48,000	121,000	−588,000
Accounts payable	11	−226,000	7
Accrued expenses and other liabilities	11	803,000	1
Net cash provided by (used in) operating activities	83	−245	−276
Maturities of marketable securities	0	61	300
Purchases of marketable securities	0	0	−63
Purchases of property and equipment	−16	−8	−22
Net cash provided by (used in) investing activities	−16	53	215
Payments made on finance lease obligations	−106,000	−157,000	−743,000
Proceeds from exercise of stock options	8	2	2
Payment of taxes withheld from net settlement of exercised options and vested RSUs	−19	0	0
Payment of deferred offering costs	−8	−1	0
Payment of third-party debt issuance costs	0	0	−2
Proceeds from the 2023 term loan, net of issuance costs	0	200	191
Repurchase of common stock	−113,000	0	0
Repayment of the Original Term Loans	0	0	−180
Issuance of the 2025 Convertible Notes, net of issuance costs	28	0	0
Issuance of the 2025 Warrants	10	0	0
Payments of 2023 term loan amendment fee	−4	0	0
Proceeds from initial public offering, net of underwriting discounts and commissions	528	0	0
Net cash provided by financing activities	665	200	10
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	130,000	−4,000	62,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	732	8	−51
Interest paid	44	49	16
Operating cash flow used for operating leases	12	11	12
Operating cash flow used for finance leases	35,000	36,000	78,000
Operating leases	4	725,000	5
Finance leases	312,000	42,000	0
Property and equipment included in accounts payable and accrued liabilities	2	2	894,000
Non-cash considerations	6	0	0
Conversion of redeemable convertible preferred stock to common stock upon initial public offering	2,386	0	0
Exercise of warrants upon initial public offering	148	0	0
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering	9	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro